160 related articles for article (PubMed ID: 10187039)
1. Surveillance for factor VIII inhibitor development in the Canadian Hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy.
Giles AR; Rivard GE; Teitel J; Walker I
Transfus Sci; 1998 Jun; 19(2):139-48. PubMed ID: 10187039
[TBL] [Abstract][Full Text] [Related]
2. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
[TBL] [Abstract][Full Text] [Related]
3. A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose.
Rubinger M; Lillicrap D; Rivard GE; Teitel J; Carcao M; Hensman C; Walker I;
Haemophilia; 2008 Mar; 14(2):281-6. PubMed ID: 18194308
[TBL] [Abstract][Full Text] [Related]
4. A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population of Canada. Association of Hemophilia Centre Directors of Canada. Factor VIII/IX Subcommittee of Scientific and Standardization Committee of International Society on Thrombosis and Haemostasis.
Giles AR; Verbruggen B; Rivard GE; Teitel J; Walker I
Thromb Haemost; 1998 Apr; 79(4):872-5. PubMed ID: 9569207
[TBL] [Abstract][Full Text] [Related]
5. Recombinant factor VIII in hemophilia A: the Canadian experience.
Blanchette VS
Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S33-9. PubMed ID: 9351535
[TBL] [Abstract][Full Text] [Related]
6. Laboratory and clinical markers of HIV infection in a national haemophilia cohort treated with recombinant factor VIII concentrate. The Association of Hemophilia Clinic Directors of Canada.
Teitel JM; Card R; Strawczynski H
Haemophilia; 1998 Sep; 4(5):731-8. PubMed ID: 9873879
[TBL] [Abstract][Full Text] [Related]
7. A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A.
Peyvandi F; Mannucci PM; Garagiola I; El-Beshlawy A; Elalfy M; Ramanan V; Eshghi P; Hanagavadi S; Varadarajan R; Karimi M; Manglani MV; Ross C; Young G; Seth T; Apte S; Nayak DM; Santagostino E; Mancuso ME; Sandoval Gonzalez AC; Mahlangu JN; Bonanad Boix S; Cerqueira M; Ewing NP; Male C; Owaidah T; Soto Arellano V; Kobrinsky NL; Majumdar S; Perez Garrido R; Sachdeva A; Simpson M; Thomas M; Zanon E; Antmen B; Kavakli K; Manco-Johnson MJ; Martinez M; Marzouka E; Mazzucconi MG; Neme D; Palomo Bravo A; Paredes Aguilera R; Prezotti A; Schmitt K; Wicklund BM; Zulfikar B; Rosendaal FR
N Engl J Med; 2016 May; 374(21):2054-64. PubMed ID: 27223147
[TBL] [Abstract][Full Text] [Related]
8. Factor VIII inhibitors in patients with hemophilia A.
Oren H; Yaprak I; Irken G
Acta Haematol; 1999; 102(1):42-6. PubMed ID: 10473887
[TBL] [Abstract][Full Text] [Related]
9. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study.
Gouw SC; van der Bom JG; Auerswald G; Ettinghausen CE; Tedgård U; van den Berg HM
Blood; 2007 Jun; 109(11):4693-7. PubMed ID: 17218379
[TBL] [Abstract][Full Text] [Related]
10. Factor VIII products and inhibitor development in severe hemophilia A.
Gouw SC; van der Bom JG; Ljung R; Escuriola C; Cid AR; Claeyssens-Donadel S; van Geet C; Kenet G; Mäkipernaa A; Molinari AC; Muntean W; Kobelt R; Rivard G; Santagostino E; Thomas A; van den Berg HM;
N Engl J Med; 2013 Jan; 368(3):231-9. PubMed ID: 23323899
[TBL] [Abstract][Full Text] [Related]
11. Cumulative inhibitor incidence in previously untreated patients with severe hemophilia A treated with plasma-derived versus recombinant factor VIII concentrates: a critical systematic review.
Franchini M; Tagliaferri A; Mengoli C; Cruciani M
Crit Rev Oncol Hematol; 2012 Jan; 81(1):82-93. PubMed ID: 21277222
[TBL] [Abstract][Full Text] [Related]
12. [Percutaneous nephrolithotripsy supported by recombinant factor VIII in a patient with hemophilia A, a Jehovah's Witness].
Azuno Y; Kaku K
Rinsho Ketsueki; 1995 Dec; 36(12):1337-41. PubMed ID: 8587168
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of the intron 22 inversion of the factor VIII gene and inhibitor development in Polish patients with severe hemophilia A.
Sawecka J; Skulimowska J; Windyga J; Lopaciuk S; Kościelak J
Arch Immunol Ther Exp (Warsz); 2005; 53(4):352-6. PubMed ID: 16088320
[TBL] [Abstract][Full Text] [Related]
14. Incidence of inhibitors in haemophilia A patients--a review of recent studies of recombinant and plasma-derived factor VIII concentrates.
Scharrer I; Bray GL; Neutzling O
Haemophilia; 1999 May; 5(3):145-54. PubMed ID: 10444280
[TBL] [Abstract][Full Text] [Related]
15. Analyses of the FranceCoag cohort support differences in immunogenicity among one plasma-derived and two recombinant factor VIII brands in boys with severe hemophilia A.
Calvez T; Chambost H; d'Oiron R; Dalibard V; Demiguel V; Doncarli A; Gruel Y; Huguenin Y; Lutz P; Rothschild C; Vinciguerra C; Goudemand J;
Haematologica; 2018 Jan; 103(1):179-189. PubMed ID: 29025913
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of recombinant factor VIII products in patients with hemophilia A.
Musso R
Drugs Today (Barc); 2008 Oct; 44(10):735-50. PubMed ID: 19137127
[TBL] [Abstract][Full Text] [Related]
17. Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates.
de Biasi R; Rocino A; Papa ML; Salerno E; Mastrullo L; De Blasi D
Thromb Haemost; 1994 May; 71(5):544-7. PubMed ID: 8091377
[TBL] [Abstract][Full Text] [Related]
18. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group.
Lusher JM; Arkin S; Abildgaard CF; Schwartz RS
N Engl J Med; 1993 Feb; 328(7):453-9. PubMed ID: 8421474
[TBL] [Abstract][Full Text] [Related]
19. Clinical evaluation of a recombinant factor VIII preparation (Kogenate) in previously untreated patients with hemophilia A.
Yoshioka A; Fukutake K; Takamatsu J; Shirahata A;
Int J Hematol; 2003 Dec; 78(5):467-74. PubMed ID: 14704043
[TBL] [Abstract][Full Text] [Related]
20. Incidence of inhibitors in patients with severe and moderate hemophilia A treated with factor VIII concentrates.
Schwarzinger I; Pabinger I; Korninger C; Haschke F; Kundi M; Niessner H; Lechner K
Am J Hematol; 1987 Mar; 24(3):241-5. PubMed ID: 3103425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]